Immutep has released the first survival data from EFTISARC NEO, a Phase II trial of its immunotherapy eftilagimod alfa in patients with soft tissue sarcoma that can be surgically removed. The results will be presented at the Connective Tissue Oncology Society annual meeting in Seoul later this month.

Syntara has paused recruitment in its Phase 1b study of SNT-9465 after some participants reported mild to moderate skin irritation from the topical scar treatment.

The Therapeutic Goods Administration has completed its inspection of Q-Gen Cell Therapeutics, the Brisbane contract manufacturer that will make Miro Sciences' StemSmart stem cell product for a planned Phase 2 trial in refractory Crohn's disease.

NuNerve is taking its lead motor neurone disease therapy into a national Phase 2 trial after early signs of disease stabilisation and functional improvement in its first human study.

CLINUVEL managing director Philippe Wolgen has rejected calls from some shareholders for a share buyback. At the company's annual general meeting in Melbourne, he said the board would keep investing cash in research and a planned business transformation.

AVITA Medical has raised its full-year revenue guidance and removed the going concern qualification from its accounts after a third quarter in which revenue grew 53 per cent on the same period last year.

Nexsen says it aims to file its RenalSure bedside test for acute kidney injury with the US Food and Drug Administration in mid-2027. It has also started a feasibility study with Austrian company GENSPEED Biotech to evaluate a second, complementary test for the condition.

Tetratherix has reworked its royalty arrangements with the University of Sydney, replacing a layered set of payment obligations with a single flat royalty that the company says will strengthen its margins as its first products approach market.

The Melbourne company dosed the first patient in its Beyond Harmony study of NTI164 on 21 September. All six sites across Victoria, Queensland, New South Wales, Tasmania and Western Australia are now open.

Neuren's chief executive, Jon Pilcher, said the result positioned the company well beyond its home market. "The Neuren team is excited about the impressive performance of DAYBUE in Q3 2026 and an outlook that continues to strengthen."

Radiopharm Theranostics has reached agreement with the US Food and Drug Administration on the design of a single pivotal Phase 3 trial for RAD101, its imaging agent for brain metastases.

Miro Sciences, formerly NeuroScientific Biopharmaceuticals, has announced that it plans to start a randomised Phase 2 trial of its StemSmart cell therapy for people with severe Crohn's disease who have failed existing treatments. 

Island Pharmaceuticals has started surgical preparations on the 22 nonhuman primates that will take part in its Galidesivir dose optimisation study for Marburg virus disease.

Executive Chairman Dr John Prendergast said Mr McKeough had served the company for over eight years. "He has made a lasting impact on the Company, both as a Director and as Chair of the Audit and Risk Committee."

Neuren Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration for NNZ-2591 as a treatment for neonatal hypoxic-ischemic encephalopathy, or HIE, a brain injury that affects newborns.

Mesoblast is farewelling two of its longest-serving and most technically experienced directors as the cell therapy company reshapes its board for what it calls the next phase of commercial delivery and growth.

Noxopharm has secured commitments for a $1.5 million placement and will offer existing shareholders up to a further $1 million to fund the next clinical study of SOF-SKN, its topical therapy for cutaneous lupus erythematosus.

The funds enable the Melbourne company to pay out its convertible note holder and avoid a further drawdown on that facility before its lead ALS drug reaches a pivotal trial readout next year.